OSR (NASDAQ:OSRH) Shares Down 5.5% – Here’s What Happened

OSR Holdings, Inc. (NASDAQ:OSRH) dropped 5.5% during mid-day trading on Tuesday . The stock traded as low as $0.4253 and last traded at $0.4375. 579,919 shares traded hands during trading, a decline of 28% from the average session volume of 803,054 shares. The stock had previously closed at $0.4628.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research note on Wednesday, June 24th. Wall Street Zen raised shares of OSR from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

OSR Price Performance

The company has a market capitalization of $15.80 million, a price-to-earnings ratio of -1.36 and a beta of 0.72. The business has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.50.

OSR (NASDAQ:OSRH) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.48 million during the quarter. OSR had a negative net margin of 363.26% and a negative return on equity of 7.24%.

Institutional Trading of OSR

A hedge fund recently bought a new position in OSR stock. Susquehanna International Group LLP acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned 0.37% of OSR as of its most recent filing with the Securities and Exchange Commission. 55.30% of the stock is owned by institutional investors and hedge funds.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.